iPSC-Derived Astrocytes

iPSC-Derived Astrocytes

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Astrocytes</th>
</tr>
<tr> [@blacher2015]
<td class="label">Lineage</td>
<td>Stem Cell > iPSC > Astrocyte</td>
</tr>
<tr>
<td class="label">Markers</td>
<td>GFAP, S100β, ALDH1L1, AQP4, EAAT1, EAAT2</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>In Vitro</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Astrocytosis</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Directed Differentiation (30-90 days)</td>
</tr>
</table>

iPSC-Derived Astrocytes

Introduction

Ipsc Derived Astrocytes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

iPSC-Derived Astrocytes are specialized glial cells generated from induced pluripotent stem cells (iPSCs) through directed differentiation protocols that recapitulate astrogliogenesis during central nervous system development.[@krencik2011] These cells express characteristic astrocytic markers including GFAP (glial fibrillary acidic protein), S100β, ALDH1L1, and the water channel AQP4, defining their identity as authentic astrocytes.[@tcw2017]

...

iPSC-Derived Astrocytes

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Astrocytes</th>
</tr>
<tr> [@blacher2015]
<td class="label">Lineage</td>
<td>Stem Cell > iPSC > Astrocyte</td>
</tr>
<tr>
<td class="label">Markers</td>
<td>GFAP, S100β, ALDH1L1, AQP4, EAAT1, EAAT2</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>In Vitro</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Astrocytosis</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Directed Differentiation (30-90 days)</td>
</tr>
</table>

iPSC-Derived Astrocytes

Introduction

Ipsc Derived Astrocytes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

iPSC-Derived Astrocytes are specialized glial cells generated from induced pluripotent stem cells (iPSCs) through directed differentiation protocols that recapitulate astrogliogenesis during central nervous system development.[@krencik2011] These cells express characteristic astrocytic markers including GFAP (glial fibrillary acidic protein), S100β, ALDH1L1, and the water channel AQP4, defining their identity as authentic astrocytes.[@tcw2017]

iPSC-derived astrocytes provide physiologically relevant in vitro models for studying neurodevelopment, neuroinflammation, and neurodegenerative diseases.[@santos2023] These cells are particularly valuable for modeling Alzheimer's disease, Parkinson's disease, and ALS, where astrocyte dysfunction plays a critical role in disease pathogenesis.[@g2024]

Differentiation Protocol

The generation of astrocytes from iPSCs typically follows a directed differentiation approach:

Stage 1: Neural Progenitor Generation (Days 0-14)

• Dual SMAD inhibition for neural induction
• Formation of neural rosettes
• Pax6, Sox2 expression

Stage 2: Astrocyte Progenitor Specification (Days 14-30)

• Exposure to CNTF, BMP, and LIF
• GFAP expression initiation
• Astrocyte progenitor proliferation

Stage 3: Astrocyte Maturation (Days 30-90)

• Acquisition of mature astrocyte markers
• S100β, ALDH1L1 expression
• Functional glutamate uptake (EAAT1/2)
• Potassium buffering capability

Astrocyte Subtypes

Proliferative Astrocytes

• Express GFAP, nestin
• Reactive astrogliosis
• Injury response

Mature Astrocytes

• S100β+, ALDH1L1+
• Normal CNS function
• Homeostatic support

Disease-Associated Astrocytes (DAA)

• Emerge in disease conditions
• Inflammatory phenotype
• Neurotoxic or neuroprotective

Marker Expression

| Marker | Type | Function |
|--------|------|----------|
| GFAP | Intermediate Filament | Astrocyte identity, reactivity |
| S100β | Calcium-binding Protein | Astrocyte maturation |
| ALDH1L1 | Enzyme | Folate metabolism |
| AQP4 | Water Channel | Water homeostasis |
| EAAT1 (GLAST) | Transporter | Glutamate uptake |
| EAAT2 (GLT1) | Transporter | Glutamate uptake |
| Connexin 43 | Gap Junction | Astrocyte coupling |

Functional Properties

Homeostatic Functions

• Ion homeostasis: Potassium buffering via Kir4.1
• Water balance: AQP4-mediated water flux
• pH regulation: Carbonic anhydrase activity
• Metabolic support: Lactate shuttling to neurons

Neurotransmitter Recycling

• Glutamate uptake: EAAT1/2-mediated clearance
• GABA recycling: Polyamine metabolism
• Monoamine metabolism: MAO activity

Synaptic Support

• Synaptogenesis: D-serine, thrombospondin release
• Synapse pruning: Complement-mediated elimination
• Neurotransmitter precursors: Glutamine production

Disease Modeling Applications

Alzheimer's Disease

iPSC-derived astrocytes from AD patients exhibit:

• Aβ clearance defects: Reduced LRP1-mediated uptake[@blacher2015]
• Inflammatory response: Increased IL-6, TNF-α secretion
• Metabolic dysfunction: Altered glycolysis
• Reactive gliosis: GFAP upregulation

Parkinson's Disease

• α-Synuclein uptake: May propagate pathology
• Inflammatory activation: Cytokine release
• Metabolic support deficits: Reduced lactate production

Amyotrophic Lateral Sclerosis (ALS)

• EAAT2 dysfunction: Reduced glutamate clearance
• Inflammatory phenotype: Pro-inflammatory cytokine release
• Support deficits: Impaired neuronal support

Co-Culture Applications

Neuron-Astrocyte Co-Cultures

• Improved neuronal maturation
• Synapse formation enhancement
• Disease mechanism studies

Triple Cultures

• Neurons, astrocytes, microglia
• More physiological modeling
• Neuroimmune interactions

Comparative Analysis

| Differentiation Method | Maturation Time | Marker Expression | Function |
|-----------------------|-----------------|------------------|----------|
| Spontaneous differentiation | 60-90 days | Variable | Research |
| CNTF/BMP patterning | 30-60 days | Robust | Disease modeling |
| Defined medium | 40-70 days | Moderate | Standardization |

Therapeutic Applications

Drug Screening

• Astrocyte-targeted therapies
• Anti-inflammatory compounds
• Metabolic modulators

Cell Therapy

• Astrocyte transplantation
• Supportive cell therapy
• Gene therapy vectors

See Also

• [Cell Types Index](/cell-types)
• [Technologies Index](/content/technologies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)amyotrophic-lateral-sclerosis-als)
• [Astrocytes](/cell-types/astrocytes)
• [Disease-Associated Astrocytes (DAA)disease-associated-astrocytes-daa)
• [GFAP](/diseases/disease-associated-astrocytes-daa](/content/diseases)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC-Derived Astrocytes discovered through SciDEX knowledge graph analysis: